Please assess the completion status of the following clinical trial:

Trial Title: hATG+CsA vs hATG+CsA+Eltrombopag for SAA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of severe or very severe aplastic anemia, defined by \[29\]:~   * At least two of the following:~     * Absolute neutrophil counts \<0.5 x 109/L (severe) or \<0.2 x 109/L (very severe)~    * Platelet counts \<20 x 109/L~    * Reticulocyte counts \<60 x 109/L~  * Hypocellular bone marrow (\<30% cellularity), without evidences of fibrosis or malignant cells~2. Male or female age \> 14 years;~3. Written informed consent~4. Willing and able to comply with all of the requirements and visits in the protocol~5. Understands that they can be randomised to either treatment arm~6. Negative pregnancy test for women of child bearing age~7. Written acceptance to use contraception (hormonal or barrier method of birth control; abstinence) for the entire duration of study participation.~Exclusion Criteria:~1. Prior immunosuppressive therapy with ATG (horse of rabbit) or any other lymphocyte depleting agent (i.e., alemtuzumab)~2. Eligibility to a sibling allogeneic stem cell transplantation~3. Evidence of a myelodysplastic syndrome, defined by the presence of myelodysplastic features, excess of blasts or karyotypic abnormalities typical of MDS (according to revised WHO 2008 criteria) \[30\],, as well as other primitive marrow disease. Patients with diagnosis of AA with cytogenetic abnormalities which are recurrent in MDS (according to revised WHO 2008 criteria) \[30\] should be included in this category, and are not eligible for the study; patients with del(20q), +8 and -Y are not included in this category, and thus are eligible for this study. The list of karyotypic abnormalities which qualifies for the diagnosis of MDS are listed in the Appendix.~4. History or clinical suspect of constitutional aplastic anemia (i.e. Fanconi Anemia with positive DEB/MMC test or Dyskeratosis Congenita)~5. History of malignant tumors with active disease within 5 years from enrollment, and/or previous chemo-radiotherapy~6. Previous history of stem cell transplantation~7. Treatment with cyclosporin A unless~   * \<4 weeks of cyclosporin A treatment before enrolement and~  * wash out period of 2 weeks before enrollment~8. CMV viremia, as defined by positive PCR or pp65 test~9. WHO performance status ≥3~10. Pregnant or breast feeding patients~11. Patients with hepatic, renal or cardiac failure, or any other life- threatening concurrent disease~12. Patients with HIV infection~13. Patients without social health care assistance~14. Participation in another clinical trial within 1 month before the start of this trial~15. Patients and/or female partners of male patients not using highly effective method of birth control i.e. intrauterine device (IUD), hormonal (oral pill, injection, implants), tubal ligation or partner's vasectomy~16. subjects with known hypersensitivity to any of the component medications~The presence of a Paroxysmal Nocturnal Hemoglobinuria clone is not an exclusion criterion.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- hATG + CsA (Type: ACTIVE_COMPARATOR): Control Arm
- hATG + CsA + Eltrombopag (Type: EXPERIMENTAL): Experimental

Based on this trial design, predict the completion outcome and termination type (if applicable).